CompletedPhase 3NCT01652664

Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients

Studying OBSOLETE: Rare genetic glaucoma

Last synced from ClinicalTrials.gov May 17, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Alcon Research
Principal Investigator: Subha Venkataraman, Clinical Project Lead
Alcon Research
Intervention: Travoprost 0.004% PQ ophthalmic solution(drug)
Enrollment: 184 enrolled
Eligibility: 17 years · All sexes
Timeline: 2012 – 2014

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01652664 on ClinicalTrials.gov

← Back to all trials